The Economic Burden of Non-Small Cell Lung Cancer Epidermal Growth Factor Receptor Mutation Positive in Indonesia

Patients with NSCLC EGFR mutations are patients with advanced stage (stage IIIb/IV)
who use targeted therapy as the main therapy such as the Tyrosine Kinase Inhibitors/TKIs (afatinib, gefitinib
and erlotinib), the number of treatments received by the patient and the worsening disease prognosis can
impact on the economic burden of patients and the Government. This study aims to determine the economic
impact of Non-Small Cell Lung Cancer with EGFR mutations in Indonesia. This research is a retrospective
observational study with a cross sectional research design that uses the perspective of health provider (health
care facilities) and societal (community) conducted at Dr Sardjito Hospital Yogyakarta and Dr Kariadi
Hospital Semarang, Indonesia. The results showed that the unit cost of therapy in Non-Small Cell Lung
Cancer patients with EGFR mutations using afatinib therapy was Rp. 120,881,289, - and in gefitinib that is
Rp. 90.750.186,-. With an average direct medical cost of Rp. 189,699, - and an indirect cost of Rp.
2.250,700